BRIDGEWATER, N.J., Oct. 8, 2013 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) announced today that an abstract related to KRYSTEXXA® (pegloticase) has been selected for poster presentation at the American Society of Nephrology (ASN) Kidney Week 2013. The annual meeting will be held November 5-10, 2013, in Atlanta, GA.
Savient's abstract, #FR-PO417, entitled "Pegloticase, a Recombinant Uricase for the Treatment of Advanced Gout, Maintains Therapeutic Concentrations During Dialysis" will be presented in a poster session titled Dialysis: Epidemiology, Outcomes, and Clinical Trials; Non-Cardiovascular I, on Friday, November 8, 2013, from 10:00am to 12:00pm ET.
ABOUT SAVIENT PHARMACEUTICALS, INC.
Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients who do not respond to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP"). Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA. In the U.S., Savient also supplies Oxandrin® (oxandrolone tablets, USP) CIII and co-promotes Kineret® (anakinra) with Swedish Orphan Biovitrum AB (Sobi). For more information, please visit the Company's website at www.savient.com.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
Certain information in this press release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that are not statements of historical fact should be considered forward-looking statements. We often use words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," "may," "predict," "will," "would," "could," "should," "target" and similar expressions to identify forward-looking statements. Actual results or events could differ materially from those indicated in forward-looking statements as a result of risks and uncertainties. For a discussion of some of the risks and important factors that we believe could cause actual results or events to differ from the forward-looking statements that we make, see the sections entitled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2013. In addition, new risks and uncertainties emerge from time to time, and it is not possible for the Company to predict or assess the impact of every factor that may cause its actual results or events to differ from those contained in any forward-looking statements. Accordingly, you should not place undue reliance on any forward-looking statements contained in this press release. Any forward-looking statements speak only as of the date of this press release. We undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise.
Savient Pharmaceuticals, Inc.
John P. Hamill
Co-President and Chief Financial Officer
Caitlyn E. Murphy
SOURCE Savient Pharmaceuticals, Inc.
|Savient Announces Multiple Abstracts Related to KRYSTEXXA® to be Presented at the 2013 ACR/ARHP Annual Meeting (2013/10/3)|
|Keryx Biopharmaceuticals' Zerenex(TM) (Ferric Citrate Coordination Complex) Data Selected for Oral and Poster Presentations at the American Society of Nephrology's Kidney Week 2013 (2013/10/17)|
|Savient Pharmaceuticals Reports Second Quarter 2013 Financial Results ()|
|Synergy Pharmaceuticals Announces Data Presentations on Plecanatide and SP-333 at Two Scientific Meetings (2013/10/3)|
|NPS Pharmaceuticals Announces FDA Acceptance of Supplemental New Drug Application for Gattex® (Teduglutide [rDNA origin]) for Injection (2013/11/13)|
|Anacor Pharmaceuticals Announces FDA Acceptance of Tavaborole NDA for Filing (2013/10/1)|
|Synergy Pharmaceuticals Announces SP-333 Data Presentation at the 17th Neurogastroenterology & Motility Scientific Meeting (2013/9/17)|
|AcelRx Pharmaceuticals Announces Data Presentations for Zalviso™ at US and International Medical Meetings (2013/10/15)|
|Astex Pharmaceuticals Announces Oral Presentation of SGI-110 AML Data at the European Cancer Congress (2013/9/30)|
|Trovagene Announces Abstracts to be Presented at Molecular Targets and Cancer Therapeutics Conference (2013/10/14)|
|Start Premium Trial||Register For Free|
|P||F||Fund Financial Data (13,000+ funds)|
|P||F||Stock Financial Data (7,000+ stocks)|
|P||F||Stock and Fund Screeners (basic)|
|P||F||Investing Articles and Market Commentary|
|P||F||Articles Archive (>30 days)|
|P||F||Discuss (dozens of stock, fund, bond, and general bulletin boards)|
|P||F||Portfolio Manager (basic)|
|P||F||Morningstar Investment Classroom|
|P||F||Access Your Portfolio Anytime, Anywhere via Your Mobile Device|
|P||Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)|
|P||Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)|
|P||Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)|
|P||Portfolio Monitor (monthly and on-demand personalized portfolio statements)|
|P||Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)|
|P||Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters|
|P||Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)|
|P||Discounts on Morningstar newsletters, books, seminars, and more|
Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.
Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.